Working... Menu

Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01022671
Recruitment Status : Completed
First Posted : December 1, 2009
Last Update Posted : January 28, 2016
Asan Medical Center
Samsung Medical Center
Seoul National University Hospital
Ulsan University Hospital
Information provided by (Responsible Party):
Chong Kun Dang Pharmaceutical

Brief Summary:
A phase II study is conducted to determine the efficacy and safety of a single agent Camtobell inj.(belotecan) on a weekly schedule in locally advanced or metastatic non-small cell lung cancer patients previously treated with chemotherapy. The usefulness of the this regimen is evaluated by response rate, median survival time, progression free survival and duration of response.

Condition or disease Intervention/treatment Phase
Carcinoma, Non-Small-Cell Lung Drug: Belotecan Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Single-Arm, Open-label, Multicenter, Phase 2 Clinical Trial to Assess the Efficacy and Safety of Single-Agent Camtobell Inj.(Belotecan) Administered on A Weekly Schedule in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Previously Treated With Chemotherapy
Study Start Date : September 2009
Actual Primary Completion Date : February 2010
Actual Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Belotecan
Single arm
Drug: Belotecan
3.0 mg/m2, Day 1, 8, 15 every 4 weeks
Other Name: Camtobell inj.

Primary Outcome Measures :
  1. Objective Response Rate [ Time Frame: every 2 cyc ]

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: 6 months after Last patient out ]
  2. Progression Free survival [ Time Frame: 6 months after Last patient out ]
  3. Adverse event [ Time Frame: every visit ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 19 Years and older
  • Histologically or cytologically confirmed locally advanced or metastatic NSCLC(Stage IIIB or IV)
  • ≥ one measureable or evaluable lesion, <25% of the bone marrow had been irradiated
  • prior platinum based chemotherapy
  • ECOG PS ≤ 2
  • Life expectancy > 3 months
  • Adequate organ function:

    • hematology: ANC ≥ 1.5×109/L, Platelet ≥ 100×109/L, hemoglobin ≥ 9.0g/dL
    • hepatic: total bilirubin ≤ 1.5×ULN, AST/ALT ≤ 2.0×ULN, ALP ≤2.0×ULN
    • renal: serum creatinine ≤ 1.5×ULN
  • Signed a written informed consent

Exclusion Criteria:

  • Active infection
  • Symptomatic brain lesion
  • Any other type of cancer during the previous 5 years except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix
  • Severe concurrent diseases
  • Prior anticancer therapy within 4 weeks before enroll
  • Active pregnancy test

Layout table for additonal information
Responsible Party: Chong Kun Dang Pharmaceutical Identifier: NCT01022671     History of Changes
Other Study ID Numbers: 11NSCLC08K
First Posted: December 1, 2009    Key Record Dates
Last Update Posted: January 28, 2016
Last Verified: January 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Chong Kun Dang Pharmaceutical:
Camtobell inj

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antineoplastic Agents, Phytogenic